These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 37042992)

  • 1. Identification of potentially high drug-like VEGFR2/c-Met dual-target type II kinase inhibitors with symmetric skeletons based on structural screening.
    Xie J; Zhang X; Meng D; Li Y; Deng P
    J Biomol Struct Dyn; 2024; 42(3):1249-1267. PubMed ID: 37042992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ligand-Based Pharmacophore Modeling, Molecular Docking, and Molecular Dynamic Studies of Dual Tyrosine Kinase Inhibitor of EGFR and VEGFR2.
    Sangande F; Julianti E; Tjahjono DH
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33096664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular dynamics guided insight, binding free energy calculations and pharmacophore-based virtual screening for the identification of potential VEGFR2 inhibitors.
    Rathi E; Kumar A; Kini SG
    J Recept Signal Transduct Res; 2019; 39(5-6):415-433. PubMed ID: 31755336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Computational Investigation of 1, 3, 4 Oxadiazole Derivatives as Lead Inhibitors of VEGFR 2 in Comparison with EGFR: Density Functional Theory, Molecular Docking and Molecular Dynamics Simulation Studies.
    Bilal MS; Ejaz SA; Zargar S; Akhtar N; Wani TA; Riaz N; Aborode AT; Siddique F; Altwaijry N; Alkahtani HM; Umar HI
    Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of novel VEGFR2-TK inhibitors by phthalimide pharmacophore based virtual screening, molecular docking, MD simulation and DFT.
    Matore BW; Roy PP; Singh J
    J Biomol Struct Dyn; 2023; 41(22):13056-13077. PubMed ID: 36775656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of octahydropyrrolo [3,2-b] pyridin derivative as a highly selective Type I inhibitor of FGFR3 over VEGFR2 by high-throughput virtual screening.
    Wang X; Ye CH; Li EM; Xu LY; Lin WQ; Chen GH
    J Cell Biochem; 2023 Feb; 124(2):221-238. PubMed ID: 36502529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High Affinity Pharmacological Profiling of Dual Inhibitors Targeting RET and VEGFR2 in Inhibition of Kinase and Angiogeneis Events in Medullary Thyroid Carcinoma.
    Dunna NR; Kandula V; Girdhar A; Pudutha A; Hussain T; Bandaru S; Nayarisseri A
    Asian Pac J Cancer Prev; 2015; 16(16):7089-95. PubMed ID: 26514495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of Phytochemicals Targeting c-Met Kinase Domain using Consensus Docking and Molecular Dynamics Simulation Studies.
    Aliebrahimi S; Montasser Kouhsari S; Ostad SN; Arab SS; Karami L
    Cell Biochem Biophys; 2018 Jun; 76(1-2):135-145. PubMed ID: 28852971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular dynamics-based insight of VEGFR-2 kinase domain: a combined study of pharmacophore modeling and molecular docking and dynamics.
    Parves MR; Riza YM; Alam S; Jaman S
    J Mol Model; 2022 Dec; 29(1):17. PubMed ID: 36550239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of tyrosine kinase inhibitors from Panax bipinnatifidus and Panax pseudoginseng for RTK-HER2 and VEGFR2 receptors, by in silico approach.
    Paul D; Mahanta S; Tag H; Das SK; Das Gupta D; Tanti B; Ananthan R; Das R; Jambhulkar S; Hui PK
    Mol Divers; 2022 Aug; 26(4):1933-1955. PubMed ID: 34554395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of dual kinase inhibitors targeting VEGFR2 and FAK: structure-based pharmacophore modeling, virtual screening, and molecular docking studies.
    Fouad MA; Osman AA; Abdelhamid NM; Rashad MW; Nabawy AY; El Kerdawy AM
    BMC Chem; 2024 Feb; 18(1):29. PubMed ID: 38347617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of potential PKC inhibitors through pharmacophore designing, 3D-QSAR and molecular dynamics simulations targeting Alzheimer's disease.
    Iqbal S; Anantha Krishnan D; Gunasekaran K
    J Biomol Struct Dyn; 2018 Nov; 36(15):4029-4044. PubMed ID: 29182053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in structure-based drug design and virtual screening of VEGFR tyrosine kinase inhibitors.
    Hoi PM; Li S; Vong CT; Tseng HH; Kwan YW; Lee SM
    Methods; 2015 Jan; 71():85-91. PubMed ID: 25239735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacophore modeling, multiple docking, and molecular dynamics studies on Wee1 kinase inhibitors.
    Hu Y; Zhou L; Zhu X; Dai D; Bao Y; Qiu Y
    J Biomol Struct Dyn; 2019 Jul; 37(10):2703-2715. PubMed ID: 30052133
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Das SK; Deka SJ; Paul D; Gupta DD; Das TJ; Maravi DK; Tag H; Hui PK
    J Biomol Struct Dyn; 2022 Sep; 40(15):6857-6867. PubMed ID: 33625319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lead generation of cysteine based mesenchymal epithelial transition (c-Met) kinase inhibitors: Using structure-based scaffold hopping, 3D-QSAR pharmacophore modeling, virtual screening, molecular docking, and molecular dynamics simulation.
    Raafat A; Mowafy S; Abouseri SM; Fouad MA; Farag NA
    Comput Biol Med; 2022 Jul; 146():105526. PubMed ID: 35487125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identifying novel therapeutic inhibitors to target FMS-like tyrosine kinase-3 (FLT3) against acute myeloid leukemia: a molecular docking, molecular dynamics, and DFT study.
    Islam MR; Osman OI; Hassan WMI
    J Biomol Struct Dyn; 2024; 42(1):82-100. PubMed ID: 36995071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-based pharmacophore mapping and virtual screening of natural products to identify polypharmacological inhibitor against c-MET/EGFR/VEGFR-2.
    Varma DA; Singh M; Wakode S; Dinesh NE; Vinaik S; Asthana S; Tiwari M
    J Biomol Struct Dyn; 2023 Apr; 41(7):2956-2970. PubMed ID: 35196966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacophore-based virtual screening of ZINC database, molecular modeling and designing new derivatives as potential HDAC6 inhibitors.
    Poonia P; Sharma M; Jha P; Chopra M
    Mol Divers; 2023 Oct; 27(5):2053-2071. PubMed ID: 36214962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-based pharmacophore modeling, virtual screening and simulation studies for the identification of potent anticancerous phytochemical lead targeting cyclin-dependent kinase 2.
    Sharma M; Sharma N; Muddassir M; Rahman QI; Dwivedi UN; Akhtar S
    J Biomol Struct Dyn; 2022; 40(20):9815-9832. PubMed ID: 34151738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.